Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca says it was resilient in Q1 2009

AstraZeneca says it was resilient in Q1 2009

1st May 2009

AstraZeneca proved to be resilient in the first quarter of the year, it has stated.

With constant exchange rates (CER), sales increased by seven per cent to $7,701 million (5,207 million pounds).

At CER, sales of Crestor ? a drug to reduce major cardiovascular events – grew by 35 per cent and emerging markets generated 15 per cent more finances than the same period last year.

David Brennan, chief executive officer of the firm, commented on the results.

He said: “The result of excellent execution in driving growth in key product franchises and in all regions, whilst delivering improvements in operating efficiency.”

The company’s full-year target, which takes into consideration an uncertain global economy and pharmaceutical industry, remains unchanged, My Brennan concluded.

Earlier this month, the Committee for Medicinal Products for Human Use issued a positive opinion supporting the drug application of Iressa (gefitinib).

The body has recommended the medication could be used to treat adults with locally advanced or metastatic non-small cell lung cancer.

Some 65,000 employees work for the company ? 51 per cent of whom operate in Europe.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.